Author | Rami D. Komrokji, MD | OncLive

Author | Rami D. Komrokji, MD


Dr. Komrokji Discusses the FDA Approval of Gilteritinib for FLT3+ AML

November 29, 2018


Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the FDA approval of gilteritinib (Xospata) for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.